Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (MULTIPRAT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Texas Children's Hospital
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Carlos Ramos, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00840853
First received: February 9, 2009
Last updated: July 20, 2016
Last verified: July 2016